CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,472 enrolled
Drug / intervention
Radium-223 dichloride (Xofigo, BAY88-8223)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02141438
NCT02141438N/ACompleted
CompareCT.gov

Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation

Bayer·observational·Posted May 19, 2014·Updated Oct 16, 2025

In Brief

An observational study evaluating Radium-223 dichloride (Xofigo, BAY88-8223) for Metastatic Castration-resistant Prostate Cancer. Completed, enrolled 1,472 participants across 68 sites in 20 countries.

Detailed Summary

Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second primary cancers.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Castration-resistant Prostate Cancer
CountriesArgentina, Austria, Belgium, Canada, Colombia, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Luxembourg, Mexico, Netherlands, Portugal, Spain, Sweden, United Kingdom, United States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 19, 2014
Enrollment StartAug 20, 2014
Primary CompletionAug 2, 2024
Study CompletionOct 24, 2024
TodayJul 2, 2026
Enrollment to primary: 10.0 yearsPosted 12.1 years ago

Interventions

Radium-223 dichloride (Xofigo, BAY88-8223)drug

This is a non-interventional study, the drug is used in its authorized indication from commercial supply. The decision to treat with Radium-223 will be agreed upon between the physician and the patient independently and prior to providing the patient study information. Treatment with Radium-223 should follow the approved local product information.